NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
36 trialsNCT02531516 2026-02-13
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT00567580 2025-05-09
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT00651326 2023-08-04
DART
Canadian Cancer Trials Group
Phase 3 Terminated
NCT05019846 2023-04-18
SPA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Recruiting
NCT00055731 2023-01-18
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
Phase 3 Completed
NCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00003653 2021-06-23
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03520478 2021-03-02
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03055312 2021-01-28
SYSUCC-007
Sun Yat-sen University
Phase 3 Terminated
NCT00004054 2020-10-22
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00023829 2020-10-22
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00030654 2020-10-22
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00003645 2020-04-28
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00002633 2020-04-03
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT00002855 2018-10-31
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002651 2017-04-17
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00021450 2016-09-02
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00243646 2016-04-14
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Schiffler Cancer Center
Phase 3 Terminated
NCT00067015 2015-12-22
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT02382094 2015-03-06
Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
Karolinska University Hospital
Phase 3 Completed
NCT00846976 2015-01-21
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00175396 2014-03-17
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
University of British Columbia
Phase 3 Unknown
NCT00884273 2013-11-13
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Phase 3 Completed
NCT00831233 2013-11-11
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Terminated
NCT00514917 2013-11-04
Rising PSA
Sanofi
Phase 3 Terminated
NCT00833248 2012-10-04
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Phase 3 Completed
NCT00014586 2012-09-24
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00657904 2012-06-06
Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00233610 2011-01-27
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Phase 3 Completed
NCT00672282 2009-05-27
SPCG6
AstraZeneca
Phase 3 Completed
NCT00841113 2009-02-11
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited
Phase 3 Completed